浸润性乳腺癌新辅助化疗后病理完全缓解的预测:治疗前乳腺超声剪切波弹性成像与超微血管成像的价值
回顾性纳入2018年11月至2022年9月间88例接受新辅助化疗及手术的浸润性乳腺癌患者,分析治疗前多参数乳腺超声(灰阶、剪切波弹性成像、超微血管成像)及临床病理因素与病理完全缓解的关系。多因素分析显示SWEmax(aOR=0.956,95%CI 0.919-0.994,P=0.025)和Ki-67指数(aOR=1.083,95%CI 1.012-1.159,P=0.021)为独立相关因素;SWEmax预测pCR的最佳阈值为134.8 kPa(AUC=0.779),Ki-67最佳阈值为27.5%(AUC=0.743),联合临床因素与SWEmax的模型AUC为0.876。
要点
- 治疗前乳腺超声SWEmax较低与浸润性乳腺癌新辅助化疗后病理完全缓解独立相关。
- SWEmax预测pCR的最佳阈值为134.8 kPa,AUC为0.779。
- 联合临床因素与SWEmax的模型诊断性能最佳,AUC为0.876。
核心结论
- 较高的Ki-67指数和治疗前乳腺超声测得的较低SWEmax与浸润性乳腺癌新辅助化疗后病理完全缓解独立相关。
研究设计与样本
- 回顾性研究,纳入2018年11月至2022年9月间88例接受新辅助化疗及后续手术的浸润性乳腺癌患者(中位年龄55岁,四分位距45,59.3),分析治疗前多参数乳腺超声(灰阶、剪切波弹性成像、超微血管成像)及临床病理因素。
关键影像表现/征象
- pCR组(n=24)较非pCR组(n=64)肿瘤尺寸显著更小、SWEmax更低、Ki-67指数更高、激素受体阴性比例更高且腋窝淋巴结转移阴性。
诊断标准与关键数值
- SWEmax预测pCR的最佳阈值为134.8 kPa,AUC为0.779。
- Ki-67指数预测pCR的最佳阈值为27.5%,AUC为0.743。
- 联合临床因素与SWEmax的模型诊断性能最佳,AUC为0.876。
- 多因素回归显示SWEmax与pCR独立相关(aOR=0.956,95%CI 0.919-0.994,P=0.025)。
- 多因素回归显示Ki-67指数与pCR独立相关(aOR=1.083,95%CI 1.012-1.159,P=0.021)。
临床应用与阅片要点
- 治疗前乳腺超声测量SWEmax和评估Ki-67指数可能有助于预测浸润性乳腺癌新辅助化疗后的病理完全缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate whether multiparametric parameters of pretreatment breast ultrasound (US) and clinicopathologic factors are associated with pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) for breast cancer.
METHODS: Between November 2018 and September 2022, 88 patients who underwent NAC and subsequent surgery were included in this study (median age, 55 years; interquartile range [IQR], 45, 59.3). Multiparametric breast US including grayscale, shear wave elastography (SWE) and superb microvascular imaging (SMI) of pathologically proven invasive breast cancers were retrospectively reviewed. Clinicopathological and multiparametric parameters of breast US, including size, SWEmax, SWEratio and vascular index on SMI (SMIVI) were compared between the groups. Univariate and multivariate logistic regression analyses were performed to determine factors predicting pCR after NAC. AUROC curve analysis was performed to determine the predictors' optimal cut-off values and diagnostic performance.
RESULTS: The pCR group (n = 24) showed a significantly smaller tumor size, lower SWEmax, higher Ki-67 index, higher hormone receptor negativity and negative axillary lymph node metastasis compared to the non-pCR group (n = 64). Multivariate regression analysis showed that SWEmax (adjusted odds ratio[aOR] = 0.956, 95 % confidence interval [CI] = 0.919-0.994, P = 0.025) and Ki-67 index (aOR = 1.083, 95 % CI = 1.012-1.159, P = 0.021) were independently associated with pathologically complete response. The optimal cut-off values for predicting pCR were 27.5 % for Ki-67 with an AUC of 0.743 and 134.8 kPa for SWEmax with an AUC of 0.779. A combination model including clinical factors and SWEmax showed the best diagnostic performance with an AUC of 0.876.
CONCLUSION: A higher Ki-67 index and lower SWEmax measured on pretreatment breast US were independently associated with pCR in invasive breast cancer after NAC.
引用
- Lee EJ, Chang YW. Prediction of complete response after neoadjuvant chemotherapy for invasive breast cancers: The utility of shear wave elastography and superb microvascular imaging in pretreatment breast ultrasound. Eur J Radiol. 2024. PMID: 38554672. doi:10.1016/j.ejrad.2024.111432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。